Medarex Inc. of Princeton, N.J., completed its initial publicoffering of 2.3 million shares of common stock and 2.3 millionredeemable warrants at $6 and 10 cents, respectively,grossing $14 million. The company originally filed for 1.5million shares of common stock and 1.5 million warrants. Thecompany now has 4.9 million shares outstanding. Rosenkrantz,Lyon & Ross Inc. is the lead underwriter.

Medarex (NASDAQ:MEDX and MEDXW) is developing therapeuticsfor AIDS and other infectious diseases, cancer, autoimmunediseases and cardiovascular disease.

(c) 1997 American Health Consultants. All rights reserved.